Instil Bio Q3 net loss narrows on lower expenses
TIL•Instil Bio reported a third-quarter net loss of $4.23 million, or 62 cents per share, as operating expenses fell to $5.99 million. It ended the quarter with $67.1 million in cash and investments and expects to fund operations through 2027.
1. Quarterly results
Instil Bio’s third-quarter net loss narrowed from a year earlier as research and development and general and administrative expenses declined. Operating expenses were $5.99 million, and the company reported a reversal of restructuring and impairment charges, compared with no such reversal in the prior-year quarter.
2. Cash and corrections
The company ended the quarter with $67.1 million in cash and investments and expects that amount as of Sept. 30, 2026, to fund operations through 2027. Instil Bio corrected prior-period financials for immaterial errors; no restatement was required.




